Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder

Abstract

Objective: Binge-eating disorder (BED) is the most prevalent eating disorder, however, few evidence-based treatments are available. The aim of this study was to evaluate the efficacy and safety of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor, in adults with BED. Methods: Patients with BED (ITT sample, N=315) were randomized to 12 weeks of double-blind treatment with once-daily, flexible-doses (4, 6, or 8 mg/d) of dasotraline or placebo. Primary endpoint was change in diary-based assessment of number of binge-eating days/week at week 12. Key secondary endpoints included changes from baseline in Clinical Global Impression, Severity scale (CGI-S), Yale-Brown Obsessive-Compulsive Scale Modified for Binge-Eating (YBOCS-BE), and percentage of subjects with cessation of binge-eating in the final 4 weeks. Results: Treatment with dasotraline was associated with a significantly greater reduction in binge-eating days/week at study endpoint (vs. placebo; LS mean [SE] difference score -0.99 [0.17]; P<0.001; effect size [ES], 0.74). Significant endpoint improvement was observed for the 3 key secondary measures, CGI-S (P<0.0001; ES, 0.95), YBOCS-BE (P<0.0001; ES, 0.96), and 4-week cessation of binge-eating (46.5% vs. 20.6%; P<0.0001). The most common adverse events in the dasotraline vs. placebo groups were insomnia (44.6% vs 8.1%), dry mouth (27.4% vs 5.0%), decreased appetite (19.7% vs 6.9%), and anxiety (17.8% vs 2.5%). Discontinuation due to adverse events occurred in 11.3% of patients on dasotraline vs. 2.5% on placebo. Conclusions: The results of this placebo-controlled, double-blind study found dasotraline to be an efficacious, safe, and generally well-tolerated treatment for BED.